GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Capricor Therapeutics
Capricor Therapeutics is a biotech company developing drugs for the treatment of Duchenne muscular dystrophy. Its stock price is highly volatile, driven by news about clinical trials and FDA decisions on its lead candidate.
Share prices of companies in the market segment - Pharma neurology
Capricor Therapeutics (CAPR) is a biotech company developing cell and exosome therapies for rare diseases, with a focus on Duchenne muscular dystrophy and other disorders. We classify it in the Pharmaceuticals/Neurology sector. The chart below shows the dynamics of this innovative biotech sector.
Broad Market Index - GURU.Markets
Capricor Therapeutics is a biopharmaceutical company developing cell and exosome therapies for the treatment of rare heart and other diseases. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Capricor compares to it.
Change in the price of a company, segment, and market as a whole per day
CAPR - Daily change in the company's share price Capricor Therapeutics
Shares of Capricor, a biopharmaceutical company, are highly volatile. Change_co measures market reaction to clinical trial data in cardiology and rare diseases. This metric is an important component of formulas on System.GURU.Markets that assess biotech risks.
Daily change in the price of a set of shares in a market segment - Pharma neurology
Capricor Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with the dynamics of CAPR, which focuses on heart disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Capricor is a biopharmaceutical company developing drugs to treat rare diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Capricor's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Capricor Therapeutics
Capricor Therapeutics' year-end performance is a story about the development of cell therapy for Duchenne muscular dystrophy. Its 12-month market cap depends entirely on clinical trial data and FDA approval. Positive results could lead to approval of the first drug for this rare and devastating disease, which would be a breakthrough for the company.
Annual dynamics of market capitalization of the market segment - Pharma neurology
Capricor Therapeutics, Inc. is a late-stage biotech developing cell therapy for Duchenne muscular dystrophy. Its stock performance is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the enormous potential of its unique technology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Capricor Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Capricor Therapeutics
Capricor, a biopharmaceutical company, has a speculative market cap. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its cell therapy for Duchenne muscular dystrophy, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
Cell therapy for heart disease is at the forefront of biotechnology. The dynamics of this sector, as shown in the chart, reflect the high level of risk and dependence on clinical trial results. Companies like Capricor Therapeutics are pursuing innovative developments in this environment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Capricor Therapeutics, a biopharmaceutical company developing cell therapies, lives in a world of clinical data. Its shares rise and fall on trial news, defying overall market trends. This chart demonstrates this independence.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Capricor Therapeutics
Capricor Therapeutics, a biotech company developing treatments for Duchenne muscular dystrophy, is at the center of medical news. Its weekly stock price is almost entirely dependent on clinical trial results and regulatory decisions, creating high volatility.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
Neuroscience-focused biotech companies like Capricor often move together, driven by shared news about breakthroughs or setbacks in brain disease treatments. The chart below illustrates this general sentiment within the niche. It allows one to gauge the market's confidence in Capricor's drugs compared to competitors' developments.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Capricor Therapeutics is a biotech company developing cell therapy for Duchenne muscular dystrophy. Its fate depends on the success of one key drug. The chart below shows how its shares navigate a world of their own, where a single piece of news can cause massive swings, ignoring the market.
Market capitalization of the company, segment and market as a whole
CAPR - Market capitalization of the company Capricor Therapeutics
Capricor Therapeutics' market capitalization reflects investors' bets on its cell therapy for Duchenne muscular dystrophy. The chart reflects the market's belief that its drug will help patients with this devastating genetic disease. Its high volatility is a direct response to clinical trial data and regulatory decisions.
CAPR - Share of the company's market capitalization Capricor Therapeutics within the market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing cell therapies for the treatment of Duchenne muscular dystrophy and other diseases. In the neuroscience segment, its market capitalization is entirely dependent on the success of its clinical programs. This metric's dynamics reflect investors' hopes that its therapies will transform the lives of patients with rare diseases.
Market capitalization of the market segment - Pharma neurology
This chart shows the overall market capitalization of the entire neuroscience pharmaceutical sector. For Capricor, which is developing cell therapy for muscular dystrophy, this line is a map of hope. The chart's rise reflects investors' belief that even the most complex and rare diseases can be treated with advanced biotechnology.
Market capitalization of all companies included in a broad market index - GURU.Markets
Capricor Therapeutics develops cell therapies for the treatment of cardiovascular and inflammatory diseases. Its market capitalization is based on its scientific approach and potential for regenerative medicine. In the overall market, this represents a significant portion of the hope for tissue repair.
Book value capitalization of the company, segment and market as a whole
CAPR - Book value capitalization of the company Capricor Therapeutics
Capricor Therapeutics develops cell and exosome therapies for rare diseases. Its book value represents its financial resources for research. It consists of cash that allows the company to conduct clinical trials. How has this research capital changed? The chart below shows.
CAPR - Share of the company's book capitalization Capricor Therapeutics within the market segment - Pharma neurology
Capricor Therapeutics develops cell therapies for the treatment of cardiac and other diseases. Its innovations require a sophisticated infrastructure: its own GMP-compliant manufacturing facilities for the production of its exosome-based drugs. The chart shows the company's share of the physical infrastructure for this cutting-edge area of regenerative medicine.
Market segment balance sheet capitalization - Pharma neurology
Capricor Therapeutics, a late-stage biopharmaceutical company, has a moderately capital-intensive business. This requires ownership of R&D and control over the manufacturing of its cell therapies. The BCap_Seg chart for the biotech sector shows that commercialization requires a substantial financial base.
Book value of all companies included in the broad market index - GURU.Markets
Capricor's balance sheet isn't its factories, but its scientific platform and clinical trial data on cell therapies for Duchenne muscular dystrophy and other diseases. The company's assets are its intellectual capital. The chart shows how this science-intensive R&D asset compares to big pharma.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Capricor Therapeutics
Capricor's balance sheet is its R&D capital. Its entire market value is a premium on the hope for success of its cell therapy for Duchenne muscular dystrophy. The chart is a visualization of these hopes, which may or may not be fulfilled based on the results of clinical trials.
Market to book capitalization ratio in a market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing cell therapies for the treatment of heart disease and other conditions. Its high valuation on this chart reflects the success of its clinical trials, which could offer new treatments for serious illnesses.
Market to book capitalization ratio for the market as a whole
Capricor Therapeutics is a biotech company developing cell therapies for muscular dystrophy and other diseases. Its market value depends almost entirely on the success of clinical trials. This chart clearly demonstrates the vast gap between its balance sheet and investor expectations.
Debts of the company, segment and market as a whole
CAPR - Company debts Capricor Therapeutics
Capricor Therapeutics, a biotech company developing cell therapies for muscular dystrophy and other diseases, is using capital to fund its late-stage clinical trials. This chart shows how the company is raising funds for this crucial development stage, which could lead to approval of its first drug.
Market segment debts - Pharma neurology
Capricor Therapeutics is a late-stage biotech company focused on treating rare diseases, particularly Duchenne muscular dystrophy. Approaching commercialization may alter its funding strategy. This chart shows how the company is funding its final research and preparing for a potential product launch.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Capricor Therapeutics
Capricor Therapeutics is a biotech company developing treatments for cardiovascular and rare diseases. Its future depends on the success of clinical trials. This chart shows its reliance on external funding, reflecting the high financial risk inherent in pharmaceutical innovation.
Market segment debt to market segment book capitalization - Pharma neurology
Capricor Therapeutics is a biotech company developing cell therapies for the treatment of Duchenne muscular dystrophy and other diseases. This is a cutting-edge but risky area of medicine. The chart shows how aggressively the sector uses debt to fund R&D, providing context for assessing Capricor's financial strategy.
Debt to book value of all companies in the market
Capricor Therapeutics, a biopharmaceutical company developing treatments for rare diseases, is at a stage where success depends on clinical trial results and funding. This chart, showing the market's overall debt load, helps us assess how typical its financial strategy is for biotech, where both risk and potential reward are high.
P/E of the company, segment and market as a whole
P/E - Capricor Therapeutics
Capricor Therapeutics is a biotech company developing cell and exosome therapies for the treatment of Duchenne muscular dystrophy and other diseases. This chart shows how investors value its innovative approaches. This value is based on clinical trial results and the potential of its drugs.
P/E of the market segment - Pharma neurology
Capricor Therapeutics is developing cell therapy. This chart shows the average valuation for the biotech sector. It emphasizes that Capricor is valued not by revenue, but by the potential of its developments to treat muscular dystrophy, which the market may value at a significant premium.
P/E of the market as a whole
Capricor Therapeutics is a biopharmaceutical company developing cell- and exosome-based therapies for rare diseases, with a particular focus on Duchenne muscular dystrophy. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether CAPR's valuation is based on confidence in the potential of its drugs or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Capricor Therapeutics
Capricor Therapeutics is a biotech company developing cell therapies for Duchenne muscular dystrophy and other diseases. This chart reflects investor expectations for the success of its clinical programs, betting that its innovative approach can help patients with rare and severe diseases.
%20P%2FE%20Capricor%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Capricor-Therapeutics&v=1772634496494 "Chart of the company's future (projected) P/E Capricor Therapeutics")
Future (projected) P/E of the market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing cell therapies for Duchenne muscular dystrophy and other rare diseases. The data here reflects the analysts' collective bet on the success of its lead candidate. It's a barometer of hope that its therapy could offer a new treatment option for patients with severe diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772634496517 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
Capricor Therapeutics is a biotech company developing treatments for rare diseases, specifically Duchenne muscular dystrophy. This sentiment chart shows how willing investors are to support companies working on drugs for orphan diseases.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772634496537 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Capricor Therapeutics
Capricor Therapeutics is a biotech company developing cell therapies for Duchenne muscular dystrophy and other diseases. This chart shows the financial costs of bringing innovative therapies to patients. It reflects investments in clinical trials that can change the lives of people with rare diseases.
Profit of companies in the market segment - Pharma neurology
Capricor Therapeutics is a biopharmaceutical company developing cell and exosome therapies for the treatment of cardiovascular and inflammatory diseases. Currently in the clinical stage, its future profitability depends on the success of its innovative treatment approaches, reflecting advances in regenerative medicine.
Overall market profit
Capricor Therapeutics is a biotech company developing cell therapies for the treatment of muscular dystrophy and other diseases. Its success depends entirely on the results of clinical trials. The overall economic situation, reflected in this chart, influences financial markets, which affect Capricor's ability to raise capital to continue its research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Capricor Therapeutics
Capricor Therapeutics is a biotech company developing cell therapies for the treatment of Duchenne muscular dystrophy and other diseases. This chart shows analysts' speculative expectations. Future profits are entirely dependent on clinical trial results and potential approval of their lead candidate.
%20profit%20of%20the%20company%20Capricor%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Capricor-Therapeutics&v=1772634496678 "Graph of future (projected) profit of the company Capricor Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing cell therapies for Duchenne muscular dystrophy and other diseases. The profitability projections for this sector, shown in this chart, reflect hopes for breakthroughs in the treatment of rare diseases. This chart helps assess how close Capricor's lead drug is to potential approval.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772634496712 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
Capricor Therapeutics is a biotech company developing cell therapies for the treatment of Duchenne muscular dystrophy and other diseases. Its success depends on the results of clinical trials. Raising capital for such research is facilitated by a strong market, which often accompanies a positive outlook, as presented here.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772634496724 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Capricor Therapeutics
Capricor Therapeutics is a biotech company developing cell therapies for Duchenne muscular dystrophy and other diseases. It may not have commercial revenue. This chart shows how investors view its potential, betting that its innovative therapy will change the lives of patients.
P/S market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing cell therapies for the treatment of Duchenne muscular dystrophy and other rare diseases. This chart shows the average revenue estimate for the sector. It helps assess the market potential for the company's developments in orphan diseases.
P/S of the market as a whole
Capricor Therapeutics is a biotech company developing exosome-based therapies, specifically for the treatment of Duchenne muscular dystrophy and other rare diseases. This chart correlates the market's valuation of the company with its actual revenues, which is important for contextualizing the analysis of companies with innovative therapeutic platforms.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Capricor Therapeutics
Capricor Therapeutics is a biotech company developing cell therapies for the treatment of Duchenne muscular dystrophy and other diseases. This chart reflects investors' high estimates of its potential future revenue. This estimate is a bet on the success of its clinical programs and regulatory approval.
%20P%2FS%20Capricor%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Capricor-Therapeutics&v=1772634496825 "The graph of the company's future (projected) P/S Capricor Therapeutics")
Future (projected) P/S of the market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing cell- and exosome-based therapies for inflammatory and fibrotic diseases. This chart compares market expectations for its future revenue with other neuroscience pharma companies. The valuation reflects investor expectations for the success of its programs in cardiology and muscular dystrophy.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772634496831 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
Capricor Therapeutics is a late-stage biotech developing therapies for Duchenne muscular dystrophy and other diseases. Its valuation depends on the success of its lead drug. This timeline of overall market expectations is irrelevant to Capricor; its fate depends on the results of clinical trials and regulatory approval.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772634496843 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Capricor Therapeutics
This chart shows the revenue of Capricor Therapeutics, a biotech company developing cell therapies for Duchenne muscular dystrophy and other diseases. Being in late-stage clinical trials, the company does not yet have stable commercial revenue, and any revenue is likely derived from grants or partnerships.
Sales of companies in the market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing cell and exosome therapies for the treatment of rare diseases, particularly Duchenne muscular dystrophy. This chart shows revenue in the neuroscience pharmaceuticals sector. It reflects the promise of regenerative medicine and the potential of Capricor's innovative approaches for treating severe genetic diseases.
Overall market sales
Capricor Therapeutics is a biotech company developing therapies for Duchenne muscular dystrophy and other diseases. Its pricing depends on the results of clinical trials. The overall economic situation, reflected in this chart, does not directly affect the need for treatment, but it does influence the investment climate in the biotech sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Capricor Therapeutics
Capricor Therapeutics is a clinical-stage biotechnology company developing treatments for rare diseases, with a particular focus on Duchenne muscular dystrophy. This projected revenue chart reflects the company's high expectations for its developments. The growth is driven by expectations for successful clinical trial results and potential approval of its cell therapy.
%20sales%20of%20the%20company%20Capricor%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Capricor-Therapeutics&v=1772634496956 "Schedule of future (projected) sales of the company Capricor Therapeutics")
Future (projected) sales of companies in the market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing cell and exosome therapies for the treatment of rare diseases, specifically Duchenne muscular dystrophy and complications of COVID-19. This chart shows projected revenue for the entire neuroscience sector, reflecting the search for innovative treatments for rare genetic diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772634496974 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
Capricor Therapeutics is a biotech company developing cell therapies for the treatment of muscular dystrophy and other diseases. Its future depends on the results of clinical trials. A positive economic environment is important for attracting investment and ensuring the stability of healthcare systems that can finance such innovative treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772634497011 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Capricor Therapeutics
Capricor Therapeutics is a clinical-stage biotech company developing therapies for Duchenne muscular dystrophy and other diseases. Its financial picture reflects its scientific mission. The chart shows operating losses, which represent investments in clinical trials of a potentially life-changing drug.
Market segment marginality - Pharma neurology
Capricor Therapeutics is a biotech company developing cell and exosome therapies for the treatment of inflammatory and fibrotic diseases, particularly Duchenne muscular dystrophy. This chart compares its operating performance to other biotech companies. Outperformance at this stage may be due to grants or payments from partners.
Market marginality as a whole
Capricor Therapeutics is a biotech company developing cell- and exosome-based therapies for rare diseases. Its success is determined not by economic cycles, but by scientific breakthroughs and clinical trial results. The potential for developing treatments for previously incurable diseases is enormous.
Employees in the company, segment and market as a whole
Number of employees in the company Capricor Therapeutics
Capricor Therapeutics is a biotech company developing cell therapies for Duchenne muscular dystrophy and other diseases. This graph shows a small team. The small staff reflects a focus on a key clinical program. Growth will depend on trial results and potential partnerships.
Share of the company's employees Capricor Therapeutics within the market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing cell therapies for muscular dystrophy and other diseases. Its team consists of a small, focused group of scientists and clinicians. This graph reflects its current status: its small staff means the company is fully focused on clinical trials.
Number of employees in the market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing cell therapies for Duchenne muscular dystrophy and other diseases. This graph illustrates the long and arduous journey of developing treatments for rare diseases. The progress of this small team of scientists and clinicians is directly dependent on clinical trial results and regulatory decisions.
Number of employees in the market as a whole
Capricor Therapeutics is a biotech company developing cell and exosome therapies for the treatment of rare heart diseases and inflammatory conditions. Its small but growing staff of scientists is an indicator of its research progress. This employment chart demonstrates that in the world of cutting-edge science, growth is driven not by economics, but by scientific data and the potential to transform medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Capricor Therapeutics (CAPR)
Capricor Therapeutics is a biotech company developing cell therapies for Duchenne muscular dystrophy and other rare diseases. This chart shows the company's enormous market value per scientist, reflecting investors' belief that the company's developments can dramatically change patients' lives and generate enormous revenue.
%20of%20the%20company%20Capricor%20Therapeutics%20(CAPR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Capricor-Therapeutics-CAPR&v=1772634497109 "Chart of market capitalization per employee (in thousands of dollars) of the company Capricor Therapeutics (CAPR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing cell therapies for cardiovascular and inflammatory diseases. This chart reflects market expectations for their leading developments. A high market capitalization per employee may indicate that investors see breakthrough potential in their treatment approach and highly value their scientific team.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772634497119 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
Capricor Therapeutics is a biotech company developing cell therapies for muscular dystrophy and other diseases. This metric reflects a business built on hope and science. Its market capitalization is based on the potential of its developments. A small team of scientists is working on developing breakthrough treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772634497135 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Capricor Therapeutics (CAPR)
Capricor Therapeutics is a late-stage biotech developing a cell therapy for Duchenne muscular dystrophy. They are not profitable. This chart shows the loss per employee. This is the cost of conducting the final, most expensive phases of clinical trials.
%20Chart%20Capricor%20Therapeutics%20(CAPR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Capricor-Therapeutics-CAPR&v=1772634497152 "Company Profit Per Employee (in thousands of dollars) Chart Capricor Therapeutics (CAPR)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing treatments for Duchenne muscular dystrophy. Being in the clinical stage, it is not profitable. This metric reflects the burn rate of R&D capital per employee, which compares favorably with benchmarks in the expensive field of rare disease treatment.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772634497165 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
Capricor Therapeutics is a biotech company developing exosome-based and cell-based therapies, primarily for cardiac and neurological diseases. These treatments are in the clinical stage. This chart shows a negative value—the "capital burn"—reflecting how much the company spends on each scientist to conduct expensive clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772634497170 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Capricor Therapeutics (CAPR)
Capricor Therapeutics is a biotech company developing cell and exosome therapies for the treatment of cardiovascular and inflammatory diseases. This schedule is typical for a clinical-stage company. Zero revenue per employee is normal, as all resources are focused on R&D.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Capricor-Therapeutics-CAPR&v=1772634497175 "Sales chart per company employee Capricor Therapeutics (CAPR)")
Sales per employee in the market segment - Pharma neurology
Capricor Therapeutics (CAPR) is a biotech company developing cell and exosome therapies for rare diseases, particularly Duchenne muscular dystrophy. This chart shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their R&D platform in the field of regenerative medicine.
Sales per employee for the market as a whole
Capricor Therapeutics (CAPR) is a biopharmaceutical company developing cell therapies for rare diseases, particularly Duchenne muscular dystrophy. This is an R&D business. The company has no commercial revenue from drug sales. This figure is currently close to zero.
Short shares by company, segment and market as a whole
Shares shorted by company Capricor Therapeutics (CAPR)
Capricor Therapeutics is a biotech company developing cell therapy for Duchenne muscular dystrophy. This chart reflects bearish bets. Bears are betting on a high risk of clinical trial failure or that even if successful, the drug will be too complex and expensive to market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Capricor-Therapeutics-CAPR&v=1772634497250 "Short Shares Chart for the Company Capricor Therapeutics (CAPR)")
Shares shorted by market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing cell therapies for rare diseases, particularly Duchenne muscular dystrophy. This metric measures pessimism. "Shorts" here represent a bet that their clinical trials will fail or prove ineffective.
Shares shorted by the overall market
Capricor Therapeutics is a clinical-stage biopharmaceutical company focused on treating rare diseases. Its success depends on science, not economics. However, this general fear graph is important. During periods of panic, investors flee risky biotechs without revenue, making it difficult for CAPR to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Capricor Therapeutics (CAPR)
Capricor Therapeutics is a biotech company working in gene therapy (based on exosomes) and the treatment of Duchenne muscular dystrophy. This chart measures the level of speculative hope. It shows when the stock is "overheated" (overbought) due to positive trial data or "oversold" due to delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Capricor-Therapeutics-CAPR&v=1772634497349 "RSI 14 indicator chart for the company's stock Capricor Therapeutics (CAPR)")
RSI 14 Market Segment - Pharma neurology
Capricor Therapeutics is a biotech company developing exosome- and cell-based therapies, focusing on Duchenne muscular dystrophy and other rare diseases. This chart measures the overall momentum in the neuroscience biotech sector. It helps determine whether the entire speculative segment is overheated by expectations.
RSI 14 for the overall market
Capricor Therapeutics, a biotech company, is critically dependent on sentiment, as reflected in this chart. Market euphoria means open capital markets, making it easy to fund expensive clinical trials. In moments of market panic, investors flee unprofitable biotechs, and companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CAPR (Capricor Therapeutics)
Capricor Therapeutics is a biotech company developing a cell therapy (CAP-1002) for the treatment of rare diseases, specifically Duchenne muscular dystrophy (DMD). This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on clinical trial success and FDA approval.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CAPR-Capricor-Therapeutics&v=1772634497443 "A chart showing analyst consensus forecasts for the expected stock price. CAPR (Capricor Therapeutics)")
The difference between the consensus estimate and the actual stock price CAPR (Capricor Therapeutics)
Capricor Therapeutics is a biotech company developing cell therapies for rare diseases, primarily Duchenne muscular dystrophy. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in the success of clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CAPR-Capricor-Therapeutics&v=1772634497467 "A chart showing the difference between the consensus forecast and the actual stock price. CAPR (Capricor Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
Capricor Therapeutics is a biotech company developing cell therapies for the treatment of Duchenne muscular dystrophy and other rare diseases. This chart shows analysts' overall expectations for the neuroscience sector, reflecting whether experts believe breakthroughs in the treatment of these complex genetic diseases are possible.
Analysts' consensus forecast for the overall market share price
Capricor Therapeutics is a biotech company developing cell therapies for Duchenne muscular dystrophy and other rare diseases. This chart shows the overall risk appetite. For Capricor, a high-risk clinical-stage company, overall market optimism is critical to raising the capital needed to fund long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Capricor Therapeutics
Capricor Therapeutics is a biotech company specializing in treating rare diseases with cell therapy. Their lead drug (CAP-1002) targets Duchenne muscular dystrophy. This graph represents a pure estimate of their R&D pipeline. Its progress depends entirely on the results of their clinical trials and FDA approval.
AKIMA Market Segment Index - Pharma neurology
Capricor (CAPR) is a clinical-stage biotech and a pioneer in cell therapy; the company is developing innovative exosome-based therapies for the treatment of Duchenne muscular dystrophy (DMD). This summary metric evaluates its R&D. The graph shows the average value for the segment. This is a benchmark: how does this ultra-niche (DMD) R&D rate (CAPR) differentiate it from the average pharma company?
The AKIM Index for the overall market
Capricor Therapeutics is a biotech company developing cell therapy for Duchenne muscular dystrophy (DMD). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story, nearing commercialization, fits in with the overall economic trends affecting the sector.
